Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
16 1월 2024 - 9:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced
leadership changes and that it is undertaking a strategic review of
its business.
Aclaris and Douglas Manion, M.D. have mutually agreed that Dr.
Manion will step down as Aclaris’ Chief Executive Officer and
President and member of the Board of Directors, effective
immediately. In connection with his departure, the Board has
appointed Dr. Neal Walker, Aclaris’ Chairman of the Board of
Directors, as Interim Chief Executive Officer. Dr. Walker is a
co-founder of Aclaris, has served as a member of the Board of
Directors since its inception, and previously served as Aclaris’
Chief Executive Officer until 2022.
“Doug joined our company as we were actively heading into later
stage development,” said Dr. Walker. “As the Company looks to reset
in 2024, we agreed that the timing was right for this transition.
On behalf of the company, I thank Doug for his many contributions
to our company and we wish him the best in his future
endeavors.”
Dr. Manion commented, “It has been a privilege to have been part
of Aclaris Therapeutics and I am proud of the work our amazing team
conducted to further scientific research.”
Concurrent with today’s announcement, Aclaris also announced
that it is conducting a strategic review of its business to
determine how to optimally deploy its capital to maximize
shareholder return. On a preliminary unaudited basis, as of
December 31, 2023, Aclaris’ aggregate cash, cash equivalents and
marketable securities was approximately $182 million.
Aclaris also reiterates the following business plans:
- ATI-1777: Aclaris is seeking a development and
commercialization partner for ATI-1777, its investigational topical
“soft” JAK 1/3 inhibitor. Aclaris recently reported positive
top-line results from its Phase 2b trial in atopic dermatitis.
- ATI-2138: Aclaris is assessing the most
effective pathway including the lead indication for ATI-2138, its
Phase 2 ready investigational oral covalent ITK/JAK3 inhibitor.
Aclaris announced positive results from its Phase 1 MAD trial of
ATI-2138 in 2023.
- Discovery: Aclaris plans to continue to
advance discovery programs through KINect®, its proprietary drug
discovery platform.
“Throughout our history, Aclaris has remained focused on
developing novel drugs where there is a lack of satisfactory
treatment options,” said Dr. Walker. “We are well capitalized and
we have recently taken the hard but necessary steps to streamline
our operations to reduce costs and preserve capital in order to put
Aclaris in an optimal position for the future.”
Aclaris has not established a timeline for the completion of its
strategic review and does not intend to comment further unless and
until its Board of Directors has approved a definitive course of
action, or it is determined that other disclosure is necessary or
appropriate.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “anticipate,” “expect,” “intend,” “may,” “plan,”
“potential,” “will,” and similar expressions, and are based on
Aclaris’ current beliefs and expectations. These forward-looking
statements include Aclaris’ expectations regarding its development
plans for its clinical and discovery programs, its plans to seek a
development and commercialization partner for ATI-1777, its plans
to undertake a strategic review of its business, and its aggregate
cash, cash equivalents and marketable securities as of December 31,
2023. These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements. Risks and uncertainties that may cause actual
results to differ materially include uncertainties inherent in the
conduct of clinical trials, Aclaris’ reliance on third parties over
which it may not always have full control, Aclaris’ ability to
enter into strategic partnerships on commercially reasonable terms,
the uncertainty regarding the macroeconomic environment and other
risks and uncertainties that are described in the Risk Factors
section of Aclaris’ Annual Report on Form 10-K for the year ended
December 31, 2022 and other filings Aclaris makes with the U.S.
Securities and Exchange Commission from time to time. These
documents are available under the “SEC Filings” page of the
“Investors” section of Aclaris’ website at www.aclaristx.com. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Aclaris as of the
date of this release, and Aclaris assumes no obligation to, and
does not intend to, update any forward-looking statements, whether
as a result of new information, future events or otherwise.
The preliminary, unaudited financial information set forth in
this press release is subject to the completion of Aclaris’ audit
process and is subject to change. The estimated preliminary results
included in this press release should not be viewed as a substitute
for Aclaris’ annual financial statements prepared in accordance
with U.S. generally accepted accounting principles. There can be no
assurance that the estimated preliminary results will be realized,
and you are cautioned not to place undue reliance on the
preliminary financial information, which reflects management’s
current expectations and anticipated results of operations, which
are subject to known and unknown risks, uncertainties and other
factors that may cause Aclaris’ actual results to differ materially
from the information presented herein.
Aclaris Therapeutics Contact:
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aclaris Therapeutics (NASDAQ:ACRS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024